Uma Kavita

机构：Spark Therapeutics (United States) · ORCID：0000-0003-2782-0896

发表论文 24 篇 · 总被引 1819 次 · h-index 19

代表论文

• Safety and immunogenicity of a recombinant M2e–flagellin influenza vaccine (STF2.4xM2e) in healthy adults (2011 · Vaccine · 被引 294)
• CD1.1 Expression by Mouse Antigen-Presenting Cells and Marginal Zone B Cells (1998 · The Journal of Immunology · 被引 231)
• Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125, STF2.HA1 SI) (2011 · Vaccine · 被引 161)
• Safety and immunogenicity of a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125) in healthy young adults (2010 · Vaccine · 被引 143)
• Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response (2012 · Vaccine · 被引 133)
• Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper (2022 · Molecular Therapy — Methods & Clinical Development · 被引 118)